Jeffrey Muilenburg
Family Medicine · Aurora, NENPI 1386652964
Payments from drug & device makers
Across 172 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$436
- Pfizer$289
- Astellas Pharma US Inc$270
- Sanofi-aventis U.S. LLC$176
- AbbVie$156
- Bayer$132
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,43496%
- Education$1114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $436 |
| Pfizer | 25 | $289 |
| Astellas Pharma US Inc | 12 | $270 |
| Sanofi-aventis U.S. LLC | 12 | $176 |
| AbbVie(2 entities) | 9 | $156 |
| Bayer | 10 | $132 |
| Boehringer Ingelheim | 8 | $119 |
| Exact Sciences | 6 | $98 |
| GSK | 7 | $90 |
| Amgen | 7 | $85 |
| Lilly USA, LLC | 5 | $77 |
| Organon | 1 | $56 |
| AstraZeneca | 4 | $52 |
| Boston Scientific | 2 | $51 |
| Genentech USA, Inc. | 4 | $49 |
| Merck | 2 | $45 |
| Johnson & Johnson | 3 | $41 |
| Novartis | 2 | $29 |
| Eisai Inc. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Dexcom, Inc. | 2 | $28 |
| Philips North America LLC | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Biogen | 1 | $11 |
How this compares
$2,545 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $62,439 |
| OzempicSemaglutide | 28 | $33,520 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $25,897 |
| JardianceEmpagliflozin | 26 | $23,451 |
| FarxigaDapagliflozin Propanediol | 29 | $23,256 |
| XareltoRivaroxaban | 42 | $20,746 |
| MyrbetriqMirabegron | 37 | $19,243 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,134 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $13,344 |
| OxycontinOxycodone Hcl | 12 | $12,531 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,808 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $8,324 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,975 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,886 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $4,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $289 | $62,43973 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $90 | $45,97598 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $52 | $34,95962 claims |
| Novo NordiskOzempic | $436 | $33,52028 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $119 | $30,42639 claims |
| Johnson & JohnsonXarelto | $41 | $20,74642 claims |
| Astellas Pharma US IncMyrbetriq | $270 | $19,24337 claims |
| MerckDulera | $45 | $4,59612 claims |
| Sanofi-aventis U.S. LLCLantus | $176 | $1,89116 claims |
| Lilly USA, LLCOlanzapine | $77 | $1,72928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Aurora
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.